Freya Biosciences named as one of Fierce Biotech’s “Fierce 15” for 2026
- Recognition reflects Freya’s scientific progress and commitment to addressing significant unmet needs in women’s health
Copenhagen, Denmark and Boston, Massachusetts, 5 October 2026: Freya Biosciences (“Freya” or “the Company”), a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces that Fierce Biotech, a division of Forge, has named it as one of 2026’s Fierce 15 biotechnology companies, designating it as one of the most innovative and promising private biotechnology companies in the industry.
